Posted by Michael Wonder on 13 May 2021
Heron Therapeutics announces U.S. FDA approval of Zynrelef for the management of post-operative pain for up to 72 hours
13 May 2021 - Full U.S. commercial launch of Zynrelef is planned for July 2021.
Heron Therapeutics today announced that the U.S. FDA has approved Zynrelef (bupivacaine and meloxicam) extended release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.
